Antabio Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$29.1M
- Investors
-
12
Antabio General Information
Description
Operator of a privately-held clinical-stage biopharmaceutical company intended for novel and differentiated antibacterial treatments of drug-resistant infections. The company's focus is on critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases, enabling health professionals to get access to medicinal products that help in curing drug-resistant diseases.
Contact Information
Website
www.antabio.comCorporate Office
- 436, Rue Pierre et Marie Curie
- 31670 Labege
- France
Corporate Office
- 436, Rue Pierre et Marie Curie
- 31670 Labege
- France
Antabio Timeline
Antabio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 28-Nov-2023 | $29.1M | Completed | Clinical Trials - Phase 1 | ||
| 8. Grant | 15-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series A) | 06-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 01-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series A) | 12-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 25-Jul-2017 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 31-Dec-2015 | Completed | Product In Beta Test | |||
| 2. Grant | 01-Jan-2015 | $4.91M | Completed | Product In Beta Test | ||
| 1. Grant | 01-Jan-2013 | $6.17M | Completed | Product In Beta Test |
Antabio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A2 Shares | ||||||||
| Ordinary | ||||||||
| A2 Shares | ||||||||
| Ordinary | ||||||||
| Ordinary | 4,440 | $1.100521 | $247.87 | $247.87 | 1x | $247.87 | 6.24% | |
| Ordinary | 3,021 | $1.100521 | $182.1 | $182.1 | 1x | $182.1 | 4.25% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Antabio Comparisons
Industry
Financing
Details
Antabio Competitors (7)
One of Antabio’s 7 competitors is BioVersys, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioVersys | Venture Capital-Backed | Basel, Switzerland | ||||
| Allecra Therapeutics | Venture Capital-Backed | Weil am Rhein, Germany | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| AiCuris | Venture Capital-Backed | Wuppertal, Germany | ||||
| Genfit | Formerly VC-backed | Loos, France |
Antabio Patents
Antabio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4125883-A1 | Combination therapy | Inactive | 24-Mar-2020 | ||
| US-20240016941-A1 | Combination therapy | Pending | 24-Mar-2020 | ||
| EP-3670512-A1 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | Inactive | 18-Dec-2018 | ||
| EP-3628672-A1 | Indane derivatives for use in the treatment of bacterial infection | Inactive | 25-Sep-2018 | ||
| EP-3628666-A1 | Indane derivatives for use in the treatment of bacterial infection | Inactive | 25-Sep-2018 | C07D277/64 |
Antabio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Antabio Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AMR Action Fund | Impact Investing | Minority | ||
| Relyens | Impact Investing | Minority | ||
| European Innovation Council Fund | Venture Capital | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| BNP Paribas Développement | PE/Buyout | Minority |
Antabio FAQs
-
When was Antabio founded?
Antabio was founded in 2009.
-
Where is Antabio headquartered?
Antabio is headquartered in Labege, France.
-
What is the size of Antabio?
Antabio has 20 total employees.
-
What industry is Antabio in?
Antabio’s primary industry is Drug Discovery.
-
Is Antabio a private or public company?
Antabio is a Private company.
-
What is Antabio’s current revenue?
The current revenue for Antabio is .
-
How much funding has Antabio raised over time?
Antabio has raised $62.5M.
-
Who are Antabio’s investors?
AMR Action Fund, Relyens, European Innovation Council Fund, Bpifrance, and BNP Paribas Développement are 5 of 12 investors who have invested in Antabio.
-
Who are Antabio’s competitors?
BioVersys, Allecra Therapeutics, Spero Therapeutics, AiCuris, and Genfit are some of the 7 competitors of Antabio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
